OmniAb, Inc.
Lilian Hernandez has an extensive work experience in the field of research. Lilian currently holds the position of Senior Research Associate at OmniAb, Inc. since November 2022. Prior to this, they worked at Ligand Pharmaceuticals as a Senior Research Associate from May 2021 to November 2022 and as a Research Associate from January 2021 to May 2021. Before joining Ligand Pharmaceuticals, they worked as a Researcher at Berkeley Lab from June 2019 to December 2020.
Lilian Hernandez attended UC San Diego from 2017 to 2019, where they pursued a Bachelor of Science degree in Global Health with a focus on Biology.
OmniAb, Inc.
The OmniAb discovery platform provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics. At the heart of the OmniAb platform is the Biological Intelligence (BI) of our proprietary transgenic animals, including OmniRat,OmniChicken and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur features unique structural attributes of cow antibodies for complex targets. OmniAb animals comprise the most diverse host systems available in the industry and they are optimally leveraged through computational antigen design and immunization methods, paired with high-throughput microfluidic-based single B cell screening and deep computational analysis of next-generation sequencing datasets to identify fully human antibodies with superior performance and developability characteristics. An established core competency focused on ion channels and transporters further differentiates our technology and creates opportunities to further leverage across modalities, including antibody-drug conjugates and others. The OmniAb suite of technologies and differentiating computational capabilities and BI features are combined to offer a highly efficient and customizable end-to-end solution for the growing discovery needs of the global pharmaceutical industry. For more information, please visit www.omniab.com.